Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV
Insulin Resistance, Cardiovascular Diseases, Heart Diseases
About this trial
This is an interventional prevention trial for Insulin Resistance
Eligibility Criteria
Inclusion Criteria: Documented HIV infection Stable antiretroviral regimen for greater than 3 months Hypertriglyceridemia (fasting triglycerides greater than 150mg/dl) Evidence of fat redistribution (e.g., increased abdominal or cervical fat, and/or decreased subcutaneous fat of the face, arms, or legs) on physical exam Exclusion Criteria: Current therapy with a lipid lowering medication (e.g., fibrates, HMG CoA reductase inhibitors, resins) or treatment with these agents in the 3 months prior to study entry Current use of hormone replacement therapy, oral contraceptives for women, or supraphysiologic testosterone therapy in men Fasting triglycerides greater than 1000mg/dl Active alcohol or substance abuse Active peptic ulcer disease History of renal failure or serum creatinine greater than 2.0 Serious opportunistic infection within the 3 months prior to study entry Hemoglobin less than 11.0 mg/dl Elevated transaminase levels (AST or ALT greater than 2.5x the upper limit of normal) Previously diagnosed diabetes mellitus or patients receiving current treatment for diabetes
Sites / Locations
- Massachusetts General Hospital